Guardant Health announced the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic to select patients with unresectable advanced or recurrent non-small cell lung cancer, or NSCLC, with HER2 mutations that has progressed after chemotherapy for treatment with Enhertu. Enhertu is a specifically engineered HER2-directed antibody drug conjugate developed by Daiichi Sankyo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health agrees decision to close COBRA study to new enrollees
- Guardant Health price target raised to $40 from $30 at Piper Sandler
- Guardant Health price target raised to $50 from $40 at Citi
- Guardant Health raises FY23 revenue view to $545M-$550M from $535M-$545M
- Guardant Health reports Q2 EPS (67c), consensus ($1.18)